Spencer MD - Search Results

1

Health status in the TORCH study of COPD: treatment efficacy and other determinants of change.

Jones PW, Anderson JA, Calverley PM, Celli BR, Ferguson GT, Jenkins C, Yates JC, Vestbo J, Spencer MD; TORCH investigators. Jones PW, et al. Among authors: spencer md. Respir Res. 2011 May 31;12(1):71. doi: 10.1186/1465-9921-12-71. Respir Res. 2011. PMID: 21627828 Free PMC article. Clinical Trial.

2

Is treatment with ICS and LABA cost-effective for COPD? Multinational economic analysis of the TORCH study.

Briggs AH, Glick HA, Lozano-Ortega G, Spencer M, Calverley PM, Jones PW, Vestbo J; TOwards a Revolution in COPD Health (TORCH) investigators. Briggs AH, et al. Eur Respir J. 2010 Mar;35(3):532-9. doi: 10.1183/09031936.00153108. Epub 2009 Aug 28. Eur Respir J. 2010. PMID: 19717476 Free article. Clinical Trial.

3

Implications of chronic obstructive pulmonary disease (COPD) on patients' health status: a western view.

Punekar YS, Rodriguez-Roisin R, Sculpher M, Jones P, Spencer M. Punekar YS, et al. Respir Med. 2007 Mar;101(3):661-9. doi: 10.1016/j.rmed.2006.06.001. Epub 2007 Jan 2. Respir Med. 2007. PMID: 17197164 Free article.

4

Prevalence of airflow obstruction in patients attending a rapid access chest pain clinic.

Francis HC, Colecliffe W, Hazell ML, Singh D, Niven R, Hagan GW, Spencer MD, Frank TL. Francis HC, et al. Among authors: spencer md. Respir Med. 2009 May;103(5):736-42. doi: 10.1016/j.rmed.2008.11.016. Epub 2008 Dec 31. Respir Med. 2009. PMID: 19118993 Free article.

5

Economic evaluation of treating chronic obstructive pulmonary disease with inhaled corticosteroids and long-acting beta2-agonists in a health maintenance organization.

Gagnon YM, Levy AR, Spencer MD, Hurley JS, Frost FJ, Mapel DW, Briggs AH. Gagnon YM, et al. Among authors: spencer md. Respir Med. 2005 Dec;99(12):1534-45. doi: 10.1016/j.rmed.2005.03.018. Respir Med. 2005. PMID: 16291076 Free article.

6

Estimating the cost-effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing data.

Briggs AH, Lozano-Ortega G, Spencer S, Bale G, Spencer MD, Burge PS. Briggs AH, et al. Among authors: spencer s, spencer md. Value Health. 2006 Jul-Aug;9(4):227-35. doi: 10.1111/j.1524-4733.2006.00106.x. Value Health. 2006. PMID: 16903992 Free article.

7

Development and validation of a prognostic index for health outcomes in chronic obstructive pulmonary disease.

Briggs A, Spencer M, Wang H, Mannino D, Sin DD. Briggs A, et al. Arch Intern Med. 2008 Jan 14;168(1):71-9. doi: 10.1001/archinternmed.2007.37. Arch Intern Med. 2008. PMID: 18195198

8

Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease.

Spencer M, Briggs AH, Grossman RF, Rance L. Spencer M, et al. Pharmacoeconomics. 2005;23(6):619-37. doi: 10.2165/00019053-200523060-00008. Pharmacoeconomics. 2005. PMID: 15960557

9

Predicting the costs of managing patients with chronic obstructive pulmonary disease.

Mapel DW, McMillan GP, Frost FJ, Hurley JS, Picchi MA, Lydick E, Spencer MD. Mapel DW, et al. Among authors: spencer md. Respir Med. 2005 Oct;99(10):1325-33. doi: 10.1016/j.rmed.2005.03.001. Epub 2005 Apr 22. Respir Med. 2005. PMID: 16140232 Free article. Clinical Trial.

10

First hundred cases of variant Creutzfeldt-Jakob disease: retrospective case note review of early psychiatric and neurological features.

Spencer MD, Knight RS, Will RG. Spencer MD, et al. BMJ. 2002 Jun 22;324(7352):1479-82. doi: 10.1136/bmj.324.7352.1479. BMJ. 2002. PMID: 12077031 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

77 results

Search Page

Filters